Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

rocket pharmaceuticals inc. - RCKT

RCKT

Close Chg Chg %
3.88 -0.15 -3.87%

Closed Market

3.73

-0.15 (3.87%)

Volume: 1.47M

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: rocket pharmaceuticals inc. - RCKT

RCKT Key Data

Open

$3.90

 Day Range

3.71 - 3.99

52 Week Range

2.19 - 11.67

 Market Cap

$420.98M

Shares Outstanding

108.22M

 Public Float

99.60M

Beta

0.47

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.25

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.04M

  

RCKT Performance

1 Week
 
 7.80%
 
1 Month
 
 10.03%
 
3 Months
 
 9.06%
 
1 Year
 
 -66.52%
 
5 Years
 
 -93.22%
 

RCKT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About rocket pharmaceuticals inc. - RCKT

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

RCKT At a Glance

Rocket Pharmaceuticals, Inc.
9 Cedarbrook Drive
Cranbury, New Jersey 08512
Phone 1-609-659-8001 Revenue 0.00
Industry Biotechnology Net Income -258,746,000.00
Sector Health Technology Employees 299
Fiscal Year-end 12 / 2025
View SEC Filings

RCKT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 2.889
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.202
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.03

RCKT Efficiency

Revenue/Employee N/A
Income Per Employee -865,371.237
Receivables Turnover N/A
Total Asset Turnover N/A

RCKT Liquidity

Current Ratio 9.296
Quick Ratio 9.296
Cash Ratio 9.152

RCKT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -47.301
Return on Equity -54.142
Return on Total Capital -52.942
Return on Invested Capital -51.709

RCKT Capital Structure

Total Debt to Total Equity 5.504
Total Debt to Total Capital 5.217
Total Debt to Total Assets 4.832
Long-Term Debt to Equity 4.888
Long-Term Debt to Total Capital 4.633
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rocket Pharmaceuticals Inc. - RCKT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
5.37M 6.27M 7.10M 9.38M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.37M 6.27M 7.10M 9.38M
Depreciation
5.37M 6.27M 7.10M 9.38M
Amortization of Intangibles
- - - -
-
COGS Growth
+369.26% +16.62% +13.28% +32.08%
Gross Income
(5.37M) (6.27M) (7.10M) (9.38M)
Gross Income Growth
-369.26% -16.62% -13.28% -32.08%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
161.97M 218.08M 252.56M 263.83M
Research & Development
120.20M 161.53M 180.97M 165.22M
Other SG&A
41.77M 56.54M 71.59M 98.61M
SGA Growth
+20.11% +34.64% +15.81% +4.46%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.88M
-
EBIT after Unusual Expense
(167.35M) (224.34M) (259.66M) (275.08M)
Non Operating Income/Expense
256.00K 3.84M 15.94M 18.22M
Non-Operating Interest Income
156.00K 3.84M 15.94M 18.22M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.98M 1.86M 1.88M 1.89M
Interest Expense Growth
-57.27% -37.45% +0.70% +0.59%
Gross Interest Expense
2.98M 1.86M 1.88M 1.89M
Interest Capitalized
- - - -
-
Pretax Income
(170.07M) (222.36M) (245.59M) (258.75M)
Pretax Income Growth
-21.74% -30.75% -10.45% -5.35%
Pretax Margin
- - - -
-
Income Tax
- - (1.00M) (500.00K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - 1.00M 500.00K
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(169.07M) (221.86M) (245.59M) (258.75M)
Minority Interest Expense
- - - -
-
Net Income
(169.07M) (221.86M) (245.59M) (258.75M)
Net Income Growth
-21.02% -31.23% -10.70% -5.35%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(169.07M) (221.86M) (245.59M) (258.75M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(169.07M) (221.86M) (245.59M) (258.75M)
EPS (Basic)
-2.6736 -3.2556 -2.9234 -2.7292
EPS (Basic) Growth
-5.99% -21.77% +10.20% +6.64%
Basic Shares Outstanding
63.24M 68.15M 84.01M 94.81M
EPS (Diluted)
-2.6736 -3.2556 -2.9234 -2.7292
EPS (Diluted) Growth
-5.99% -21.77% +10.20% +6.64%
Diluted Shares Outstanding
63.24M 68.15M 84.01M 94.81M
EBITDA
(161.97M) (218.08M) (252.56M) (263.83M)
EBITDA Growth
-20.11% -34.64% -15.81% -4.46%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 7.955
Number of Ratings 15 Current Quarters Estimate -0.444
FY Report Date 03 / 2026 Current Year's Estimate -1.565
Last Quarter’s Earnings -0.43 Median PE on CY Estimate N/A
Year Ago Earnings -2.05 Next Fiscal Year Estimate -1.301
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 6 10 7
Mean Estimate -0.44 -0.41 -1.56 -1.30
High Estimates -0.37 -0.34 -1.30 -0.74
Low Estimate -0.52 -0.50 -1.83 -2.01
Coefficient of Variance -13.89 -13.72 -11.58 -34.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 0 0 0
HOLD 6 6 7
UNDERWEIGHT 0 0 0
SELL 2 2 1
MEAN Overweight Overweight Overweight

Insider Actions for Rocket Pharmaceuticals Inc. - RCKT

Date Name Shares Transaction Value
Nov 21, 2025 John C. Militello See Remarks 65,920 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.98 per share 196,441.60
Nov 21, 2025 Martin L. Wilson General Counsel 383,816 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.98 per share 1,143,771.68
Nov 21, 2025 Gaurav D. Shah CEO; Director 778,296 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.98 per share 2,319,322.08
Nov 21, 2025 Jonathan David Schwartz See Remarks 299,064 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.98 per share 891,210.72
Oct 9, 2025 Syed Rizvi Chief Medical Officer 283,018 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 9, 2025 Syed Rizvi Chief Medical Officer 345,911 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 9, 2025 Syed Rizvi Chief Medical Officer 383,854 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 23, 2025 Roderick Tze Ian Wong Director 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 23, 2025 Roderick Tze Ian Wong Director 47,667 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 23, 2025 Piratip Pratumsuwan Director 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 9, 2025 Aaron Ondrey Chief Financial Officer 128,173 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.88 per share 369,138.24
May 21, 2025 Kinnari Patel See Remarks 442,694 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.53 per share 2,890,791.82
Feb 28, 2025 Jonathan David Schwartz See Remarks 166,949 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $18.5 per share 3,088,556.50
Feb 28, 2025 Jonathan David Schwartz See Remarks 163,852 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.05 per share 2,138,268.60
Feb 28, 2025 Jonathan David Schwartz See Remarks 237,638 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.58 per share 2,514,210.04

Rocket Pharmaceuticals Inc. in the News